RGEN

#3874
Repligen Corp
128.7300
-2.13%
Сектор:
Базовая:
Валюта прибыли:
Дневной диапазон
128.6300
128.7300
Годовой диапазон
120.0000
175.5700
Дневное изменение
-2.13%
Месячное изменение
-20.22%
6-месячное изменение
-22.31%
Годовое изменение
-22.31%
Предыдущее закрытие
131.5350
Open
128.6300
Bid
Ask
Low
128.6300
High
128.7300
Объем
142
Open full chart

Financials

Overview Отчетность Statistics Dividends
Quarterly Annual
  • Market Capitalization 7.243 M
  • Employee 1 778
  • Founded 1981
  • CEO Tony J. Hunt
  • Website www.repligen.com
  • Headquarter Delaware, United States
  • FIGI BBG000BS48J3
  • Industry Technology
Total revenue
Net income
Basic earnings per share (Basic EPS)
Total debt
Free cash flow
Cash & equivalents
Price to earnings ratio
190.53
Price to sales ratio
—
Dividends per share
—
Dividend yield %
—

Repligen Corporation

Repligen Corporation is a global life sciences company devoted to the development and commercialization of innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs. The company is based in Waltham, Massachusetts, and was incorporated in Delaware in 1981. A public company, Repligen is listed on the NASDAQ exchange under the symbol RGEN. As of 2025, Repligen employs over 1,900 employees globally and serves primarily biopharmaceutical drug developers and contract development and manufacturing organizations worldwide.

Новости